📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
351 analysed today
FollowTelegram
351
Today
149,752
All-time analysed
42,937
Positive
6,664
Negative
91,466
Neutral
8,617
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
250 announcements match the current filters (relevance ≥ 5).
Marshall Machines 5th CoC Meeting: Resolution Plan De-sealed and Transaction Audit Discussed
Marshall Machines Limited is currently undergoing the Corporate Insolvency Resolution Process (CIRP), with the 5th Committee of Creditors (CoC) meeting held on February 26, 2026. A significant development is the de-sealing of a Resolution Plan submitted by a prospective applicant, indicating progress toward a potential turnaround. The CoC also discussed the Transaction Audit Report and the methodology for asset valuation. E-voting on several items, including the non-disclosure of fair value and ratification of costs, is scheduled to conclude on March 5, 2026.
Key Highlights
5th CoC meeting held on February 26, 2026, to progress the insolvency resolution process.
De-sealing of a Resolution Plan submitted by a Prospective Resolution Applicant (PRA) was a key agenda item.
Discussion held on the Transaction Audit Report and the methodology for valuing the Corporate Debtor's assets.
E-voting for agenda items, including CIRP cost ratification, runs from February 28 to March 5, 2026.
Proposal to approve non-disclosure of fair value in the Information Memorandum as per new IBBI regulations.
👀 What to Watch
Investors should remain extremely cautious as the company is in insolvency, which typically results in significant equity dilution or total loss. Monitor the outcome of the resolution plan evaluation to see if the company can successfully emerge from CIRP.
Vaishali Pharma to Acquire 51.02% of Kesar Pharma; Preferential Issue at Rs 20 Per Share
Vaishali Pharma has issued a corrigendum to its postal ballot notice regarding the acquisition of a 51.02% stake in Kesar Pharma Limited. The deal involves a preferential issue of shares at Rs 20 each, which is significantly higher than the SEBI-mandated floor price of Rs 09.46. The floor price was derived from the 90-day volume-weighted average price (VWAP) as per regulatory requirements. Shareholders have until March 15, 2026, to cast or modify their votes based on these updated disclosures.
Key Highlights
Proposed acquisition of a 51.02% majority stake in Kesar Pharma Limited
Preferential shares to be issued at Rs 20 per share, a 111% premium over the floor price of Rs 09.46
Floor price based on 90-day VWAP of Rs 09.46 and 10-day VWAP of Rs 08.02
Relevant date for the transaction pricing is February 13, 2026
E-voting facility for shareholders is open until 05:00 PM on March 15, 2026
👀 What to Watch
Investors should monitor the successful integration of Kesar Pharma as it represents a significant majority acquisition. The high issue price relative to the floor price is a positive signal regarding the company's internal valuation.
Shalby Increases Stake in Subsidiary PK Healthcare to 91.13% via Rs 59.6 Cr Rights Issue
Shalby Limited has increased its stake in its subsidiary, PK Healthcare Private Limited (PKHPL), from 87.26% to 91.13%. The company invested approximately Rs 59.60 crore by subscribing to 5.96 crore equity shares at a price of Rs 10 per share through a rights issue. The capital infusion will be utilized by PKHPL for debt repayment and working capital requirements. PKHPL, which focuses on the Delhi/NCR healthcare market, reported a turnover of Rs 91.19 crore in FY 2024-25.
Key Highlights
Acquired 5,96,01,950 equity shares of PK Healthcare at Rs 10 per share
Total investment amount stands at Rs 59,60,19,500
Shalby's shareholding in PKHPL increased from 87.26% to 91.13%
Funds will be used by the subsidiary for debt repayment and working capital
PKHPL's turnover grew from Rs 67.36 crore in FY23 to Rs 91.19 crore in FY25
👀 What to Watch
This move consolidates control and helps deleverage a key subsidiary in the high-growth Delhi/NCR region. Investors should monitor if this capital infusion leads to improved consolidated margins for Shalby in the coming quarters.
Chalet Hotels to Invest ₹633 Crore for New 330-Room Luxury Hotel in Hyderabad
Chalet Hotels has approved the development of a new luxury hotel in Madhapur, Hyderabad, featuring approximately 330 rooms and 36,255 sq. ft. of retail space. The project involves a total investment of approximately Rs. 6,328 million, which will be funded through a combination of internal accruals and debt. This facility will be the company's third hotel in the Hyderabad market and is expected to be operational by FY2029. The development will be part of a building premises obtained on a warm shell lease, aligning with the company's asset-light expansion strategy.
Key Highlights
Proposed development of a ~330-room luxury hotel in Madhapur, Hyderabad
Includes ~36,255 sq. ft. of commercial and retail space within the premises
Total estimated investment of ~Rs. 6,328 million including security deposits
Project completion targeted for FY2029, financed via debt and internal accruals
Marks the company's third hotel property in the Hyderabad region
👀 What to Watch
Investors should view this as a long-term growth driver that strengthens Chalet's footprint in a key business hub. Monitor the company's debt-to-equity ratio as it executes this capital-intensive project over the next three years.
Chalet Hotels to invest ₹633 Cr for new 330-room luxury hotel in Hyderabad
Chalet Hotels has approved the development of a new luxury hotel project in the Madhapur area of Hyderabad, marking its third property in the city. The project will feature approximately 330 rooms and 36,255 sq. ft. of commercial and retail space. The company has earmarked an investment of Rs. 6,328 million (approx. ₹633 crore) for this development, which will be funded through a mix of internal accruals and debt. The project is expected to be completed and operational by FY2029.
Key Highlights
Total investment outlay of approximately Rs. 6,328 million including security deposits
Addition of ~330 luxury rooms and ~36,255 sq. ft. of commercial/retail space
Project to be developed on a warm shell lease basis in the Madhapur IT hub
Targeted completion and operationalization by the end of FY2029
Funding to be managed through a combination of debt and internal accruals
👀 What to Watch
Investors should look at this as a significant long-term capacity expansion in a high-demand micro-market. While the gestation period is long (FY2029), it strengthens the company's portfolio in the premium hospitality segment.
Marshall Machines Updates on CIRP; CoC Approves 90-Day Extension for Insolvency Process
Marshall Machines Limited is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. Recent Committee of Creditors (CoC) meetings have finalized the issuance of Form G to invite potential resolution applicants and established an evaluation matrix for bids. Crucially, the CoC has approved a 90-day extension for the completion of the CIRP to allow more time for the submission and vetting of resolution plans. The company has also replaced its Interim Resolution Professional with Mavent Restructuring Services LLP to lead the process.
Key Highlights
CoC approved the replacement of the IRP with Mavent Restructuring Service LLP as the Resolution Professional.
Issuance of Form G for Expression of Interest (EOI) to identify prospective resolution applicants has been initiated.
Approved filing an application for a 90-day extension to the statutory timeline for completing the CIRP.
Request for Resolution Plan (RFRP) and Evaluation Matrix for assessing potential bids have been finalized.
Ratified various administrative costs including fees for valuers, forensic auditors, and legal counsel.
👀 What to Watch
Investors should remain highly cautious as equity shareholders typically face significant dilution or total loss of value during insolvency proceedings. Monitor the NCLT's approval of the extension and the quality of resolution plans submitted by prospective applicants.
Shalby Q3 FY26: Consolidated PAT Turns Positive at ₹1.3 Cr; MedTech Revenue Jumps 29% YoY
Shalby Limited reported a marginal 0.6% YoY decline in consolidated revenue to ₹279.4 crores for Q3 FY26, while consolidated PAT turned positive at ₹1.3 crores compared to a loss in the previous year. The core hospital business faced headwinds with a 2.6% revenue decline and lower occupancy of 44%, primarily due to ongoing negotiations with major insurance providers. Conversely, the MedTech segment showed strong momentum with 29% revenue growth and achieved EBITDA breakeven for the first time. The company maintains a stable balance sheet with a net debt of ₹408 crores and a low gearing ratio of 0.41x.
Key Highlights
Consolidated PAT improved to ₹1.3 crores from a loss of ₹3 crores in the same quarter last year.
MedTech segment revenue grew 29% YoY to ₹30.38 crores, with EBITDA turning positive at ₹0.7 million.
Hospital standalone revenue declined 2.6% YoY to ₹221 crores with occupancy dropping to 44% from 46%.
ARPOB (Average Revenue Per Occupied Bed) saw a marginal increase of 1.1% YoY to ₹43,171.
Shalby International (Gurgaon) reported revenue of ₹23.9 crores with 51% contribution from international patients.
👀 What to Watch
Investors should monitor the recovery in hospital occupancy once insurance negotiations are finalized and track the scalability of the now-profitable MedTech division. The stock remains a watch as the company transitions its medical implant business from a turnaround to a growth phase.
Chalet Hotels Secures Stay from Karnataka HC on Rs 39.56 Cr Property Tax Notice
Chalet Hotels Limited has successfully obtained a stay order from the High Court of Karnataka against a property sale notice issued by the Greater Bengaluru Authority. The dispute involves alleged non-payment of property tax dues amounting to approximately Rs 39.56 crore, which includes interest, penalties, and cess. The notice pertained to the company's property located in Whitefield, Bengaluru. This legal intervention prevents the immediate sale of the asset until the next hearing date, providing temporary relief to the company.
Key Highlights
High Court of Karnataka granted a stay order on the 'Proclamation and Written Notice of Sale' of the Whitefield property.
The total disputed amount claimed by the Greater Bengaluru Authority is approximately Rs 39.56 crore.
The claim includes principal property tax, interest, penalties, and applicable cess.
The stay order remains effective until the next scheduled date of hearing in the Writ Petition filed by the company.
👀 What to Watch
Investors should monitor the final court ruling as a negative outcome would require a cash outflow of Rs 39.56 crore. The current stay is a positive procedural development that protects the company's Bengaluru asset from immediate liquidation.
Vaishali Pharma to Issue 61.23 Lakh Shares for 33.24% Stake in Kesar Pharma
Vaishali Pharma Limited has issued a postal ballot notice to seek shareholder approval for a preferential allotment of 61.23 lakh equity shares. The shares are priced at Rs. 20 each, representing a total transaction value of approximately Rs. 12.25 crores. This is a non-cash transaction involving a share swap to acquire a 33.24% stake in Kesar Pharma Limited, an associate company. The e-voting period for shareholders is scheduled from February 14 to March 15, 2026.
Key Highlights
Preferential issue of up to 61,23,000 equity shares at an issue price of Rs. 20 per share
Total consideration of Rs. 12.25 crores to be settled via share swap (non-cash)
Acquisition of 21,52,575 shares in Kesar Pharma Limited, representing a 33.24% stake
Relevant date for floor price determination fixed as February 13, 2026
E-voting results to be announced on or before March 17, 2026
👀 What to Watch
Investors should assess the strategic value of consolidating the stake in Kesar Pharma against the equity dilution caused by the new share issuance. Monitor the final approval and subsequent integration of Kesar Pharma's operations.
Shah Alloys Q3 Profit at ₹35.22 Cr Driven by ₹67.46 Cr Asset Sale; Main Plant Closed
Shah Alloys reported a net profit of ₹35.22 Crores for Q3 FY26, a turnaround from a loss of ₹15.26 Crores in the previous year, entirely due to exceptional gains of ₹67.46 Crores from asset and investment sales. Revenue from operations plummeted 80% YoY to ₹10.29 Crores as the company's primary Iron and Steel plant has been shut down since August 2025 due to technology obsolescence. Auditors have issued a qualified opinion, flagging material uncertainty regarding the company's status as a 'Going Concern' and noting the non-provision of ₹36.55 lakhs in bank interest. The company is currently exploring options for its future after liquidating significant plant machinery and its stake in SAL Steel Limited.
Key Highlights
Net Profit of ₹35.22 Crores in Q3 FY26 vs a Loss of ₹15.26 Crores in Q3 FY25, driven by one-time gains.
Exceptional items of ₹67.46 Crores include a ₹53.47 Crore gain from selling plant/machinery and a ₹13.98 Crore gain from SAL Steel share sale.
Revenue from operations fell sharply to ₹10.29 Crores from ₹51.90 Crores YoY following the closure of the Santej plant.
Auditors expressed inability to confirm 'Going Concern' status as the main manufacturing facility is no longer operational.
Qualified opinion issued for non-provision of ₹36.55 lakhs in interest on bank loans for the quarter.
👀 What to Watch
Investors should treat the reported profit as a non-recurring event resulting from asset liquidation rather than operational strength. Given the plant closure and auditor warnings on 'Going Concern' status, the stock carries high risk and requires a cautious approach until a new business model is established.
Halder Venture Q3 Profit Falls YoY; Announces ₹30.16 Cr Acquisition of Inqube Technologies
Halder Venture Limited reported a standalone net profit of ₹2.17 crore for Q3 FY26, a sharp decline from ₹13.45 crore in the same quarter last year, though it showed sequential improvement from Q2. The company has approved a strategic acquisition of a 52% stake in Inqube Technologies for ₹30.16 crore to diversify into Agri-ERP and carbon credit markets. Operationally, the company has started packaging at its Haldia unit, capitalizing ₹22.45 crore. However, auditors have raised concerns regarding a pending ₹6.05 crore dividend from a foreign subsidiary that remains uncollected.
Key Highlights
Standalone Net Profit for Q3 FY26 at ₹2.17 crore, down 83.8% YoY from ₹13.45 crore.
Approved acquisition of 52% stake in Inqube Technologies Private Limited for ₹30.16 crores.
Revenue from operations fell to ₹73.63 crore in Q3 FY26 from ₹286.97 crore in Q3 FY25.
Capitalized ₹22.45 crore following the operationalization of packaging units at the Haldia Manufacturing Unit.
Auditors highlighted a potential impairment risk for ₹6.05 crore in dividend income receivable from a foreign subsidiary.
👀 What to Watch
Investors should closely monitor the execution of the Inqube acquisition and the recovery of the ₹6.05 crore dividend from the foreign subsidiary. While the YoY earnings drop is concerning, the operationalization of the Haldia unit and the new tech-focused acquisition are key long-term growth drivers to track.
Halder Venture Fined ₹5.43 Lakh by BSE for Board Composition Non-Compliance
Halder Venture Limited has been penalized ₹5,42,800 by BSE for failing to comply with SEBI Regulation 17(1) regarding board composition during the September 2025 quarter. The company explained that the lapse occurred during the transition period following an amalgamation that made corporate governance norms applicable. Management confirmed that the company became fully compliant on November 14, 2025, and has since filed a waiver application with the exchange. The Board has reviewed the matter and advised the management to exercise abundant caution to ensure future regulatory adherence.
Key Highlights
BSE imposed a total fine of ₹5,42,800 (including ₹82,800 GST) for non-compliance with Regulation 17(1).
The company achieved full compliance with board composition requirements on November 14, 2025.
A waiver application for the levied fine was filed with BSE on December 1, 2025.
The regulatory lapse followed a Scheme of Amalgamation that became effective on January 1, 2025.
👀 What to Watch
Investors should note the governance lapse but also recognize that the company has already rectified the board composition. Monitor the outcome of the waiver application and ensure no further regulatory delays occur in future filings.
Halder Venture to Acquire 52% Stake in Inqube Technologies for ₹30.16 Crores
Halder Venture Limited has approved the acquisition of a 52% controlling stake in Inqube Technologies Private Limited for ₹30.16 crores, aimed at integrating cloud-based Agri-ERP solutions and entering the carbon credits market. For the quarter ended December 31, 2025, the company reported standalone revenue of ₹73.63 crores and a net profit of ₹2.17 crores. The company also operationalized its Haldia packaging unit, capitalizing ₹22.45 crores in the process. However, auditors highlighted a pending dividend of ₹6.05 crores from a foreign subsidiary that remains uncollected.
Key Highlights
Acquisition of 52% stake in Inqube Technologies for ₹30.16 crores to be completed in tranches over 24 months.
Standalone Q3 FY26 revenue reported at ₹7,363.09 lakhs with a net profit of ₹217.10 lakhs.
Capitalized ₹2,244.57 lakhs following the operationalization of packaging units at the Haldia Manufacturing facility.
Auditors flagged a delay in receiving ₹605.07 lakhs dividend income from foreign subsidiary Hal Exim Pte Limited.
Strategic entry into carbon credit commercialization and tech-driven agricultural value chain efficiency.
👀 What to Watch
Investors should monitor the successful integration of Inqube's tech platform and the timely repatriation of the ₹6.05 crore dividend from the foreign subsidiary. The operationalization of the Haldia unit is a positive sign for future production capacity.
Halder Venture Q3 Net Profit Jumps 105% YoY to ₹2.17 Cr; Announces 52% Stake Buy in InQube
Halder Venture reported a robust performance for Q3 FY26, with standalone revenue growing 28.8% YoY to ₹73.63 crore and net profit doubling to ₹2.17 crore. The company is aggressively expanding, having operationalized its Haldia Manufacturing Unit and announcing a ₹30.16 crore acquisition of a 52% stake in InQube Technologies to enter the Agri-ERP and carbon credit markets. However, investors should monitor an auditor's emphasis regarding a delayed ₹6.05 crore dividend from a foreign subsidiary. For the nine-month period, net profit stands significantly higher at ₹13.45 crore compared to ₹7.15 crore in the previous year.
Key Highlights
Standalone Net Profit for Q3 FY26 surged 105% YoY to ₹217.10 lakhs from ₹105.76 lakhs.
Revenue from operations increased by 28.8% YoY to ₹7,363.09 lakhs compared to ₹5,716.92 lakhs.
Approved acquisition of 52% stake in InQube Technologies for ₹3,016 lakhs to enter Agri-ERP and carbon credit sectors.
Capitalized ₹2,244.57 lakhs for packaging operations at the Haldia Manufacturing Unit during the quarter.
Auditor raised an emphasis of matter regarding ₹605.07 lakhs in delayed dividend income from a foreign subsidiary.
👀 What to Watch
The strong earnings growth and strategic diversification into agri-tech are positive indicators, but investors should seek clarity on the recoverability of the ₹6.05 crore foreign dividend highlighted by auditors.
Halder Venture Q3 Profit Doubles to ₹2.17 Cr; Acquires 52% Stake in Inqube for ₹30.16 Cr
Halder Venture reported a strong performance for Q3 FY26, with revenue from operations reaching ₹7,363.09 lakhs compared to ₹5,716.92 lakhs in the same quarter last year. The company's net profit more than doubled to ₹217.10 lakhs from ₹105.76 lakhs YoY. Additionally, the board approved a strategic acquisition of a 52% stake in Inqube Technologies for ₹30.16 crores to enter the Agri-ERP and carbon credit markets. However, investors should note an auditor's observation regarding a delayed dividend of ₹605.07 lakhs from a foreign subsidiary.
Key Highlights
Revenue from operations grew to ₹7,363.09 lakhs in Q3 FY26 from ₹5,716.92 lakhs in Q3 FY25.
Net profit for the quarter increased by 105% YoY to ₹217.10 lakhs.
Board approved 52% stake acquisition in Inqube Technologies for ₹30.16 crores to be completed within 24 months.
Capitalized ₹2,244.57 lakhs following the operationalization of packaging units at the Haldia facility.
Auditors highlighted a pending dividend receivable of ₹605.07 lakhs from a foreign subsidiary, though management claims it is not credit impaired.
👀 What to Watch
Investors should view the strong earnings growth and tech-focused acquisition as positive long-term drivers. Monitor the recovery of the ₹6.05 crore dividend from the foreign subsidiary as highlighted by auditors to ensure no future impairments.
Vaishali Pharma Approves Rs 12.25 Cr Share Swap for Kesar Pharma Stake
Vaishali Pharma has approved the issuance of 61.23 lakh equity shares at Rs 20 each via a preferential allotment. This is a non-cash transaction involving a share swap to acquire 21.52 lakh shares of its associate company, Kesar Pharma Limited, at Rs 56.89 per share. The total value of the issuance is approximately Rs 12.25 Crores, resulting in Kesar Pharma holding a 4.48% stake in the company. Additionally, the board has cleared the unaudited financial results for the quarter and nine months ended December 31, 2025.
Key Highlights
Issuance of 61,23,000 equity shares at a price of Rs 20 per share
Total deal value of Rs 12.246 Crores via share swap for Kesar Pharma stake
Acquisition of 21,52,575 shares of Kesar Pharma Limited at Rs 56.89 per share
Post-allotment, Kesar Pharma Limited will own 4.48% of Vaishali Pharma
Board approved Q3 FY26 results and initiated a postal ballot for shareholder approval
👀 What to Watch
Investors should evaluate the valuation of Kesar Pharma and the impact of the 4.48% equity dilution on earnings per share. Watch for the detailed Q3 financial performance to assess the company's growth trajectory.
Vaishali Pharma to Issue 61.23 Lakh Shares via Swap for Kesar Pharma Stake
Vaishali Pharma has approved a preferential allotment of 61.23 lakh equity shares at an issue price of ₹20 per share, totaling approximately ₹12.25 crores. This is a non-cash transaction executed via a share swap to subscribe to 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. Post-allotment, Kesar Pharma will hold a 4.48% stake in Vaishali Pharma. The board also approved the unaudited financial results for the quarter ended December 31, 2025.
Key Highlights
Preferential issue of 61,23,000 equity shares at ₹20 each (including ₹18 premium).
Total transaction value for the share swap is ₹12,24,60,000.
Acquisition of 21,52,575 shares of associate company Kesar Pharma Limited at ₹56.89 per share.
Post-issue, Kesar Pharma Limited will hold a 4.48% equity stake in Vaishali Pharma.
Board approved Q3 FY26 financial results and initiated a Postal Ballot for shareholder approval.
👀 What to Watch
Investors should monitor the strategic benefits of increasing the stake in Kesar Pharma and review the Q3 financial results for operational performance. The share swap indicates a consolidation of interests with its associate company.
Vaishali Pharma to Issue Shares Worth ₹12.25 Cr via Swap for Kesar Pharma Stake
Vaishali Pharma's board has approved a preferential allotment of 61.23 lakh equity shares at ₹20 per share, totaling ₹12.25 crore. This is a non-cash transaction executed via a share swap to acquire 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. The board also cleared the unaudited financial results for the quarter ended December 31, 2025. This move will result in Kesar Pharma Limited holding a 4.48% stake in Vaishali Pharma post-allotment.
Key Highlights
Issuance of 61,23,000 equity shares at ₹20 per share aggregating to ₹12.246 Crores.
Transaction involves a share swap for 21,52,575 shares of associate company Kesar Pharma.
Kesar Pharma Limited to hold 4.48% post-issue equity in Vaishali Pharma.
Board approved Q3 and 9M FY26 financial results during the same meeting.
Relevant date for floor price determination set as February 13, 2026.
👀 What to Watch
Investors should review the Q3 financial performance and assess the strategic value of increasing the stake in Kesar Pharma. Monitor the upcoming postal ballot results for shareholder approval of this preferential issue.
Simbhaoli Sugars Q3 Results: Accumulated Unprovided Interest Reaches ₹2,010 Crore Amid CIRP
Simbhaoli Sugars Limited reported its Q3 FY26 results under the supervision of an Interim Resolution Professional (IRP) due to ongoing insolvency proceedings. The auditors have issued a heavily qualified report, noting that the company failed to provide for interest expenses on bank borrowings amounting to ₹8,941.03 Lakhs for the quarter. Total accumulated unprovided interest has now reached a massive ₹2,01,022.71 Lakhs, significantly understating the company's reported losses and liabilities. Furthermore, the company has not conducted mandatory impairment testing for its ₹224 Crore investment in its power subsidiary.
Key Highlights
Unprovided interest on bank borrowings for Q3 FY26 stands at ₹8,941.03 Lakhs, understating net loss.
Total accumulated unprovided interest on bank debt reached ₹2,01,022.71 Lakhs (approx ₹2,010 Crore) as of Dec 2025.
Auditors flagged unprovided interest of ₹121.63 Crore on delayed sugarcane price payments to farmers.
No impairment assessment performed on subsidiary investments (₹224.26 Crore) or Property, Plant & Equipment.
Potential contravention of Section 197 regarding management remuneration totaling over ₹411 Lakhs without lender consent.
👀 What to Watch
Investors should remain extremely cautious as the company is under insolvency (CIRP) and the financial statements do not reflect the true scale of debt. The stock remains highly speculative given the massive unprovided liabilities and ongoing legal proceedings at NCLAT.
Simbhaoli Sugars Q3 Results: Unprovided Interest Reaches ₹2,010 Crore Amid Insolvency
Simbhaoli Sugars is currently under the Corporate Insolvency Resolution Process (CIRP), with operations managed by an Interim Resolution Professional (IRP). The company reported its Q3 FY26 results with significant audit qualifications, most notably the non-provision of interest on bank borrowings amounting to ₹8,941.03 Lakhs for the quarter. Total accumulated unprovided interest has now reached ₹2,01,022.71 Lakhs, meaning the reported losses are significantly understated. Furthermore, the company has not assessed impairment for its assets or its ₹23,000+ Lakhs investment in subsidiaries.
Key Highlights
Unprovided interest on bank borrowings for the quarter ended Dec 2025 is ₹8,941.03 Lakhs.
Total accumulated interest expense not provided for in the accounts stands at ₹2,01,022.71 Lakhs.
Interest on delayed cane price payments to farmers amounting to ₹12,163.25 Lakhs remains unprovided.
Company failed to conduct mandatory impairment testing for subsidiary investments totaling ₹23,080.51 Lakhs.
Management powers remain suspended as the company undergoes CIRP following an NCLT order dated July 11, 2024.
👀 What to Watch
Investors should be extremely wary as the company is in insolvency and the financial statements significantly understate liabilities due to missing interest provisions. The risk of total equity erosion is high given the massive debt and ongoing legal proceedings at NCLAT.
